New compound V-161 offers hope in the fight against antibiotic-resistant bacteria

V-161, a novel compound targeting the Na+ -V-ATPase enzyme in vancomycin-resistant Enterococcus faecium (VRE), significantly reduces bacterial growth and colonization.

MEDICLIN presents preliminary figures for the 2024 financial year – Biotech Investments

EQS-News: MEDICLIN AG / Key word(s): Preliminary Results MEDICLIN presents preliminary figures for the 2024 financial year 27.02.2025 / 13:03 CET/CEST The issuer is solely

February 28, 2025

Docs Decry ICU Closure; Outpatient Facility Fees; Hospitals Eye Sports Centers

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. Clinicians Protest ICU Closure at Minnesota

March 28, 2024

Bone Mineral Density Deficits Prevalent Among Childhood Cancer Survivors

Survivors of childhood cancer face challenges from bone mineral density (BMD) deficits due to treatment exposures and other factors, some of which may be modifiable,

January 11, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.